CMPX Compass Therapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of compasstherapeutics.com (CMPX)

Patent protection for targeted antibodies minimizes price wars, which stimulates the implementation of automated molecule screening. The EV/Sales multiple valuation of Compass Therapeutics (CMPX) confirms this correlation, where the current status is 0.00. Strategic management of the scientific portfolio and clinical data ensures overall stability, transforming innovations into effective oncology treatment methods.

Company Value to Revenue: Compass Therapeutics Inc (CMPX) for 11/23/2025 - 11/19/2026

compasstherapeutics.com - analytical breakdowns and key metrics (CMPX)

- share price and consensus valuation forecast:
Initial company analysis:Compass Therapeutics CMPX
Product sample of Compass Therapeutics

The absence of geopolitical barriers in the field of cancer immunotherapy provides Compass Therapeutics (CMPX) with a stable environment for global research. This business resilience is reflected in the EV/Sales ratio, which relates the total enterprise value to its revenue, excluding the impact of debt load. This metric allows for the valuation of each dollar of sales without distortions from the capital structure. Analyzing this figure reveals whether the asset is overbought or undervalued. The trajectory of the EV/Sales ratio serves as an indicator of the balance between fundamental value and market expectations.

Competitor analysis for Compass Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP